A 12-week treatment for eosinophilic esophagitis (EoE) in patients 11 years of age and older. EOHILIA has not been shown to be safe and effective for longer than 12 weeks.1

Illustration of esophageal inflammation



EOHILIA is the only FDA-approved oral corticosteroid for EoE.1

Shake-responsive viscosity + anti-inflammatory effect

What makes EOHILIA different

EOHILIA is designed with a viscosity that can change—upon shaking, it gets more fluid and then regains viscosity to flow slower.1,2 This ability to go from low to high viscosity is known as “thixotropic.”2

Mechanism of action

  • Inflammation is a core component in the pathogenesis of EoE. Although the precise mechanism of corticosteroid actions on inflammation is not known, budesonide has a wide range of inhibitory activities against multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators involved in allergic inflammation.1
  • Budesonide is an anti-inflammatory corticosteroid with a high glucocorticoid effect and a weak mineralocorticoid effect.1
  • EOHILIA is 200 times more potent than cortisol and 15 times more potent than prednisone alone1

EOHILIA is supplied in premixed stick packs to offer your patients reliable dosing that doesn’t require measuring or mixing when taken as recommended in the Prescribing Information.1

Illustration of EOHILIA metabolism

EOHILIA metabolism

Budesonide—the active ingredient in EOHILIA—has a high plasma clearance, 0.9 to 1.8 L/min approaching the estimated liver blood flow, suggesting that budesonide is a high hepatic clearance drug.1

  • The mean plasma elimination half-life (t1/2) of budesonide after administration of EOHILIA was 3.3 hours1
  • Following oral absorption, budesonide is subject to high first pass metabolism (80% to 90%)1
  • The oral bioavailability of budesonide in healthy subjects is estimated to be 14% under fasting state1

Request a visit with a representative to answer your questions and learn more about EOHILIA.


  1. EOHILIA (budesonide oral suspension) Prescribing Information. Takeda Pharmaceuticals, Inc.
  2. Lee CH, Moturi V, Lee Y. J Control Release. 2009;136(2):88-98.